{"gao_id": "GAO-23-105477", "published": "2023-03-15T12:00:00Z", "released": "2023-03-15T08:00:00Z", "summary": "The Orange Book is a list of FDA-approved drugs. It helps generic drug companies identify when patents for brand name drugs will expire so they can market generic equivalents. For makers of brand name drugs, listing patents gives them time to resolve patent disputes before a generic can be offered for sale. Views varied, but some stakeholders had concerns that certain patent listing practices can...", "title": "Generic Drugs: Stakeholder Views on Improving FDA's Information on Patents", "topics": ["Generic drugs", "Health care", "Publications", "Agency evaluations", "Health Care", "Drugs", "Litigation", "Prescription drugs", "Patent infringement", "Intellectual property rights", "Patents"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-23-105477", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-23-105477-highlights.pdf"}, {"title": "Full Report (46 pages)", "url": "https://www.gao.gov/assets/gao-23-105477.pdf"}, {"title": "Accessible PDF (52 pages)", "url": "https://www.gao.gov/assets/820/818197.pdf"}]}